IPM Take
Lilly does not need neuroscience to rescue its current growth story. Mounjaro generated $9.9 billion and Zepbound $4.9 billion in the second quarter of 2026, against company-wide revenue of $23.0 billion. Tirzepatide is already doing the heavy commercial lifting.
What matters is what Lilly is doing with that position.
The company completed its $6.3 billion upfront acquisition of Centessa in June, adding an orexin receptor 2 agonist portfolio centred on cleminorexton. Weeks later, it agreed to acquire AtaiBeckley for approximately $2.8 billion upfront, with another potential $1 billion tied to milestones, bringing in rapid-acting neuroplastogens for treatment-resistant depression. Its internal pipeline also includes remternetug for Alzheimer’s disease and a gene therapy specifically for Parkinson’s disease associated with GBA1 mutations.
The signal is bigger than corporate diversification. Lilly is assembling a neuroscience portfolio around distinct biological mechanisms and increasingly selected patient populations. If that model succeeds, the bottleneck will not simply be finding effective drugs. Health systems will also need the biomarkers, genetic testing, specialist pathways and monitoring capacity required to identify the patients for whom those drugs make sense.
Precision neuroscience becomes meaningless if the precision exists only in the molecule.
Executive Summary
Eli Lilly remains commercially dominated by cardiometabolic medicines. In Q2 2026, Mounjaro sales reached $9.9 billion and Zepbound sales $4.9 billion, while total company revenue was approximately $23.0 billion. By comparison, Kisunla, Lilly’s marketed anti-amyloid therapy for Alzheimer’s disease, generated $167 million during the quarter.
However, Lilly is rapidly broadening its neuroscience portfolio.
Its completed acquisition of Centessa added a pipeline of orexin receptor 2 agonists, including cleminorexton, which Lilly now lists in development for central disorders of hypersomnolence. The transaction had an upfront equity value of approximately $6.3 billion, with up to $1.5 billion more linked to development milestones.
In July, Lilly announced a definitive agreement to acquire AtaiBeckley for approximately $2.8 billion upfront, plus up to $1 billion in contingent value rights. Its lead candidate, BPL-003, is an intranasal formulation of mebufotenin benzoate being developed for treatment-resistant depression, while VLS-01 is a buccal DMT formulation in Phase 2b development. The deal had not yet been reported as completed as of 8 September.
Lilly’s own pipeline reinforces the same direction. Remternetug targets deposited amyloid plaque and is being studied in cognitively unimpaired people and those with mild cognitive impairment due to Alzheimer’s disease. A separate GBA1 gene therapy is being developed specifically for Parkinson’s disease associated with GBA1 mutations.
Why it matters
- HTA bodies: The value of increasingly targeted neurological medicines will depend partly on the diagnostic infrastructure needed to identify eligible patients. Assessments may need to incorporate biomarker testing, genetic stratification, imaging and monitoring rather than evaluating the medicine as an isolated intervention.
- Payers: Precision neuroscience can create narrower treatment populations but more complex and expensive care pathways. Reimbursement decisions will increasingly determine not only whether a drug is covered, but whether patients can access the tests and specialists required to reach that treatment.
- Industry / innovation partners: Lilly’s spending shows that major pharma is willing to place large bets across fundamentally different neuroscience mechanisms. The competition is shifting from broad diagnostic categories toward biological pathways, disease stages and molecularly defined subgroups.
Eli Lilly’s current growth story is easy to understand. Tirzepatide is enormous.
Mounjaro and Zepbound together generated close to $15 billion in the second quarter of 2026, giving Lilly a commercial position few pharmaceutical companies have ever enjoyed from a single molecular franchise.
But the more interesting question is what Lilly is building while that engine is running.
Neuroscience remains commercially small by comparison, yet Lilly has been assembling a portfolio that looks increasingly different from the traditional model of developing one broadly acting drug for a broad neurological diagnosis.
Kisunla already illustrates the shift. The anti-amyloid antibody is approved for Alzheimer’s disease, but treatment is initiated in patients with mild cognitive impairment or mild dementia, the population studied in clinical trials, and requires confirmed amyloid pathology. Safety management also involves MRI monitoring because of amyloid-related imaging abnormalities, with APOE ε4 genotype affecting ARIA risk.
The therapy therefore arrives with an infrastructure requirement attached to it. The right diagnosis is no longer enough. Disease stage, biomarker status and individual safety risk matter too.
Lilly’s pipeline pushes that logic further.
Remternetug is another amyloid-directed biologic, but Lilly is studying it in cognitively unimpaired people and those with mild cognitive impairment due to Alzheimer’s disease. Its GBA1 programme narrows the population still further, targeting Parkinson’s disease in patients with GBA1 mutations.
This is where neuroscience begins to resemble oncology: one familiar disease label may increasingly conceal several biologically distinct treatment populations.
Lilly is buying mechanisms, not just indications
The company’s recent acquisitions make the strategy clearer.
Centessa brought Lilly cleminorexton and a broader orexin receptor 2 agonist platform. Orexin signalling is central to regulation of wakefulness, and Lilly is now developing cleminorexton for central disorders of hypersomnolence. The $6.3 billion upfront price suggests Lilly sees the platform as considerably more than another symptomatic sleep medicine.
AtaiBeckley takes Lilly into another part of neuroscience entirely. Its lead programme, BPL-003, is being developed for treatment-resistant depression and is designed around rapid neuroplastic effects rather than the conventional monoamine mechanisms that have dominated antidepressant pharmacology. Lilly’s proposed acquisition values the company at about $2.8 billion upfront, with further payments linked to development and regulatory milestones.
These programmes remain scientifically and commercially uncertain. Clinical-stage neuroscience has a long history of expensive failures, and novel mechanisms do not become transformative simply because they are biologically elegant.
But the portfolio reveals a coherent strategic direction.
Amyloid, orexin, GBA1 and neuroplasticity are not one therapeutic platform. What connects them is a willingness to define neurological disease through increasingly specific biology and then build treatment around that biology.
The healthcare system may become the limiting technology
This creates a policy problem that drug development alone cannot solve.
A GBA1-targeted therapy requires patients to be genetically identified. Amyloid-directed treatment depends on early diagnosis and confirmation of pathology. New interventional psychiatric medicines may require specialised administration, observation and follow-up models that ordinary antidepressant prescribing does not.
The drug therefore becomes only one part of the precision-medicine pathway.
That has direct implications for HTA and reimbursement. A medicine may demonstrate value in a carefully selected trial population while producing disappointing real-world access if diagnostic capacity is concentrated in a few specialist centres or the associated testing is not reimbursed.
Lilly’s current revenues may still be driven overwhelmingly by cardiometabolic medicine, and there is no evidence yet that neuroscience will become a comparable commercial franchise.
The stronger signal is strategic.
Tirzepatide has given Lilly extraordinary scale at precisely the moment neuroscience is becoming more biomarker-driven, genetically stratified and mechanistically ambitious. Lilly is using that opportunity to buy and build across those emerging categories before their commercial value is clear.
The next neuroscience winners may therefore be determined by more than which company develops the best molecule.
They may be determined by whether healthcare systems become precise enough to find the patients that molecule was built for.
